U.S. flag An official website of the United States government
  1. Home
  2. Drugs
  3. Development & Approval Process (Drugs)
  4. Development Resources
  5. Ceftolozane Tazobactam – Injection products
  1. Development & Approval Process (Drugs)

Ceftolozane Tazobactam – Injection products

Ceftolozane Tazobactam – Injection products

Recognized Interpretive Criteria

Exceptions to the recognized standard of CLSI M100

Additional FDA-identified interpretive criteria

 

Minimum Inhibitory
Concentrations

(mcg/mL)

Disk Diffusion
(zone diameter in mm)

Pathogen

S

I

R

S

I

R

Enterobacteriaceae

M-100 standard is recognized

>22

19-21

<18

Pseudomonas aeruginosa

M-100 standard is recognized

Streptococcus spp Viridans
Group

M-100 standard is recognized

-

-

-

Bacteroides fragilis

≤8/4

16/4

≥32/4

-

-

-

Haemophilus influenzae

≤0.5/4

-

-

-

-

-

S = Susceptible; I = Intermediate; R = Resistant

STIC are based on a dose for adults of 1.5g every 8 h for the treatment of complicated intra-abdominal infections and complicated urinary tract infections or a dose of 3 g every 8 h for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.